← Back to Search

Unknown

EDP-235 SAD Cohorts for COVID-19

Phase 1
Waitlist Available
Research Sponsored by Enanta Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 14 days in hv mad cohorts
Awards & highlights

Study Summary

This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 14 days in hv mad cohorts
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 14 days in hv mad cohorts for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety measured by adverse events
Secondary outcome measures
AUC of EDP-235
Cmax of EDP-235

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: EDP-235 SAD CohortsExperimental Treatment1 Intervention
EDP-235 Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5, orally, once daily in one single administration
Group II: EDP-235 MAD CohortsExperimental Treatment1 Intervention
EDP-235 Dose 1, Dose 2 and Dose 3 orally, once daily for 7 days
Group III: EDP-235 SAD Placebo CohortsPlacebo Group1 Intervention
Matching placebo, orally, once daily in one single administration
Group IV: EDP-235 MAD Placebo CohortsPlacebo Group1 Intervention
Matching placebo, orally, once daily for 7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EDP-235
2022
Completed Phase 1
~140

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Enanta PharmaceuticalsLead Sponsor
33 Previous Clinical Trials
2,276 Total Patients Enrolled
Enanta Pharmaceuticals, IncLead Sponsor
39 Previous Clinical Trials
2,912 Total Patients Enrolled
3 Trials studying COVID-19
260 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of EDP-235 in Healthy Subjects
2022. "A Study of EDP-235 in Healthy Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05246878.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top